Guggenheim assumed coverage on shares of Menlo Therapeutics (NASDAQ:MNLO) in a research report report published on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $52.00 price objective on the stock.

Menlo Therapeutics (NASDAQ:MNLO) opened at $33.96 on Monday. Menlo Therapeutics has a one year low of $20.50 and a one year high of $39.86.

In other Menlo Therapeutics news, major shareholder Vivo Capital Surplus Fund Viii bought 294,118 shares of the business’s stock in a transaction dated Thursday, January 25th. The stock was acquired at an average cost of $17.00 per share, with a total value of $5,000,006.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

ILLEGAL ACTIVITY NOTICE: “Menlo Therapeutics (MNLO) Now Covered by Guggenheim” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The Company offers VPD-737 (serlopitant), a potent oral NK1 receptor antagonist for the treatment of severe, chronic pruritus associated with or without a diagnosed disease.

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with's FREE daily email newsletter.